Home > Insider Trading > Filing (0001104659-19-037458)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1404955	Loring Seth Harrison	C/O Akero Therapeutics, Inc. 170 Harbor Way, 3Rd Floor South San Francisco CA 94080		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-06-24	4,228,764	$0.00	4,228,764	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-06-24	286,439	$0.00	4,515,203	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-06-24	900,000	$16.00	5,415,203	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-06-24	13,000,000	$0.00	4,228,764	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-06-24	880,568	$0.00	286,439	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. ("ATP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP.
On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.